ADC Evaluation in Solid Tumor Models

Creative Biolabs provides a large variety of xenograft human cancer models and bioanalytical methods to support antibody-drug conjugate (ADC) therapeutic potential studies. With well-trained scientists with excellent surgical skills, extensive knowledge and expertise in in vivo experimentation, as well as advanced facilities and technological platform, we are dedicated to develop both orthotopic and subcutaneous xenograft models for various challenges in ADC in vivo evaluation projects.

Xenograft Tumor Model

Creative Biolabs is in possession of a diverse selection of immunodeficient mice for xenograft tumor model creation. Murine xenograft tumor models (heterotopic xenograft models and orthotopic xenograft models) are widely used for anti-cancer therapeutics studies to evaluate their tumor suppression capabilities against various solid tumors.

  • Creation of heterotopic xenograft models:

Heterotopic xenograft models are developed by injecting tumor cells or malignant into thymic nude mice, severely compromised immunodeficient (SCID) mice, or other immunocompromised mice. Subcutaneous implantation is most common for these models and based on the quantity of injected cancer cells, tumor will form and growth within a short period of time (several weeks or months).

  • Creation of orthotopic xenograft models:

To create orthotopic xenograft models, tumor cells or tissues are usually injected into the tumor originating organs of the immunodeficient mice. Similar to heterotopic xenograft models, tumor will emerge and develop within a short period of time to the desired sizes. Comparing to the heterotopic xenograft models, the orthotopic model is more advantageous in that the solid tumor exerts similar microenvironment as the original tumor and it is more suitable for metastasis studies.

Creative Biolabs maintains a wide variety of human cancer cell lines for xenograft tumor model development:

Condition Target Cell Line
Pancreatic cancer CD74, CD227, nectin-4 Capan-1, Capan-2, CFPAC-1, HPAF-II, MIAPaCa-2, PANC-1
Breast cancer CD174, GPNMB, CRIPTO, nectin-4, LIV1A, HER2 Bcap-37, BT-474, ZR-751, ZR-75-30, MKN-28, NCL-N87
Ovarian cancer MUC16, TIM-1, mesothelin ES-2, HO-8910PM, PA-1, SK-OV-3
Melanoma GD2, GPNMB, ED-B, PMEL 17, endothelin B receptor A375, B16, A2058, C32, SK-MEL-30
Prostate PSMA, STEAP-1, TENB2 22Rv1, CL-1, DU145, PC-3
Renal CAIX, TIM-1 OS-RC-2, 768-O, ACHN
Mesothelioma Mesothelin
Colorectal cancer CD74, CD174, CD227, CD326, CRIPTO, FAP, ED-B COLO201, COLO205, COLO320DM, CW-2, HCT-8, HCT-15, HCT116, SW480, SW620
Lung CD56, CD326, CRIPTO, FAP, mesothelin, GD2, 5T4 NCL-H526, NCL-H1688, NCL-H69, NCL-H146, NCL-H209, NCL-H446, NCL-H226
Multiple myeloma CD56, CD74, CD138, endothelin B receptor KMS-26, RPMI-8226, KMS-11

Information Derived from Xenograft Tumor Model

Various information regarding the efficacy of an ADC can be extrapolated using xenograft tumor models. Standard measurements include body weight change, food consumption, physiological tumor growth curve, tumor mass weight, and tumor suppression rate. Additional analysis, including ELISA & western blotting, immunohistochemistry, H&E staining, and RT-qPCR that evaluate more detailed impacts of the ADC on tumor can also be made to obtain a comprehensive picture of ADC in vivo efficacy.

Bioluminescent Xenograft Model

Tumor size and volume in subcutaneous xenograft model can be directly measured and calculated by vernier caliper. However, this method is not applicable for orthotopic or non-subcutaneous xegnograft models. Creative Biolabs offers non-invasive imaging systems to monitor tumor growth, metastatic dissemination, and response to therapeutic treatments. By transducing cancer cell to express firefly luciferase, implanted tumor cells can produce bioluminescent signal after injection of D-luciferin. Our experts are experienced in cancer cell transducing as well as imaging to offer efficient ADC efficacy assessments.

Orthotopic implantation of HT-29 colorectal  tumor cells and bioluminescent imaging of mice model over time (J Mol Biol & Mol Imaging, 2015). Orthotopic implantation of HT-29 colorectal tumor cells and bioluminescent imaging of mice model over time (J Mol Biol & Mol Imaging, 2015).

Reference

  1. Fernández, Y.; et al. Bioluminescent imaging of animal models for human colorectal cancer tumor growth and metastatic dissemination to clinically significant sites. J Mol Biol & Mol Imaging. 2015, 2(2): 1019.

For Research Use Only. NOT FOR CLINICAL USE.


Related Sections

ADC <em>In Vivo</em> Analysis: One-stop ADC Development Service: Services:
Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:









Customized FluoroAb™

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Contact us
USA
 
 Tel:
 Fax:
 Email:
Europe
 
 Tel:
 Email:
Germany
 
 Tel:
 Email:


Inquiry

Top